Enflonsia™ (clesrovimab-cfor) – New drug approval
June 9, 2025 - Merck announced the FDA approval of Enflonsia (clesrovimab-cfor), for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
Download PDF
